ReviewViruses2012
Advanced vaccine candidates for Lassa fever.
Review in Viruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.PLoS neglected tropical diseases · 2026Article
- Lassa virus protein-protein interactions as mediators of Lassa fever pathogenesis.Virology journal · 2025Review
- Lassa virus NP DEDDh 3'-5' exoribonuclease activity is required for optimal viral RNA replication and mutation control.bioRxiv : the preprint server for biology · 2023Article
- Vaccine Candidates against Arenavirus Infections.Vaccines · 2023Review
- Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023Article
- Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments.Virulence · 2021Review
- Severe fever with thrombocytopenia syndrome with re-infection in China: a case report.Infectious diseases of poverty · 2021Article
- Management of Lassa Fever: A Current Update.Cureus · 2021Review
- Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.Viruses · 2021Article
- Lassa Virus, but Not Highly Pathogenic New World Arenaviruses, Restricts Immunostimulatory Double-Stranded RNA Accumulation during Infection.Journal of virology · 2020Article
- Vaccine platforms for the prevention of Lassa fever.Immunology letters · 2019Review
- Pre-clinical development of a vaccine against Lassa fever.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2018Article
- Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.Vaccine · 2018Article
- Current research for a vaccine against Lassa hemorrhagic fever virus.Drug design, development and therapy · 2018Review
- Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.NPJ vaccines · 2018Review
- Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.Human vaccines & immunotherapeutics · 2017Review
- Vaccines for epidemic infections and the role of CEPI.Human vaccines & immunotherapeutics · 2017Review
- A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.Human vaccines & immunotherapeutics · 2017Article
- Highly Pathogenic New World Arenavirus Infection Activates the Pattern Recognition Receptor Protein Kinase R without Attenuating Virus Replication in Human Cells.Journal of virology · 2017Article
- Immunobiology of Ebola and Lassa virus infections.Nature reviews. Immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Lassa virus (LASV) is the most prominent human pathogen of the Arenaviridae. The virus is transmitted to humans by a rodent reservoir, Mastomys natalensis, and is capable of causing lethal Lassa Fever (LF). LASV has the highest human impact of any of the viral hemorrhagic fevers (with the exception of Dengue Fever) with an estimated several hundred thousand infections annually, resulting in thousands of deaths in Western Africa. The sizeable disease burden, numerous imported cases of LF in non-endemic countries, and the possibility that LASV can be used as an agent of biological warfare make a strong case for vaccine development. Presently there is no licensed vaccine against LF or approved treatment. Recently, several promising vaccine candidates have been developed which can potentially target different groups at risk. The purpose of this manuscript is to review the LASV pathogenesis and immune mechanisms involved in protection. The current status of pre-clinical development of the advanced vaccine candidates that have been tested in non-human primates will be discussed. Major scientific, manufacturing, and regulatory challenges will also be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.